Researchers to test new treatment for AML

06/6/2010 | Gainesville Sun (Fla.), The

Researchers at the University of Florida Shands Cancer Center in Gainesville have received FDA approval for a Phase I trial of Oxi4503, an experimental treatment that damages leukemia cells and eliminates the blood vessels that allow the cells to thrive. The trial will involve patients with acute myelogenous leukemia who are no longer responding to standard treatments.

View Full Article in:

Gainesville Sun (Fla.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC